Literature DB >> 28277323

Individualized Anesthetic Management for Patients Undergoing Electroconvulsive Therapy: A Review of Current Practice.

Ethan O Bryson1, Amy S Aloysi, Kate G Farber, Charles H Kellner.   

Abstract

Electroconvulsive therapy (ECT) remains an indispensable treatment for severe psychiatric illness. It is practiced extensively in the United States and around the world, yet there is little guidance for anesthesiologists involved with this common practice. Communication between the anesthesiologist and the proceduralist is particularly important for ECT, because the choice of anesthetic and management of physiologic sequelae of the therapeutic seizure can directly impact both the efficacy and safety of the treatment. In this review, we examine the literature on anesthetic management for ECT. A casual or "one-size-fits-all" approach may lead to less-than-optimal outcomes; customizing the anesthetic management for each patient is essential and can significantly increase treatment success rate and patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28277323     DOI: 10.1213/ANE.0000000000001873

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Modified Anesthesia Protocol for Electroconvulsive Therapy Permits Reduction in Aerosol-Generating Bag-Mask Ventilation during the COVID-19 Pandemic.

Authors:  James Luccarelli; Claudia Fernandez-Robles; Carlos Fernandez-Robles; Ryan J Horvath; Sheri Berg; Thomas H McCoy; Stephen J Seiner; Michael E Henry
Journal:  Psychother Psychosom       Date:  2020-06-18       Impact factor: 17.659

2.  Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.

Authors:  Sarah H Lisanby; Shawn M McClintock; George Alexopoulos; Samuel H Bailine; Elisabeth Bernhardt; Mimi C Briggs; C Munro Cullum; Zhi-De Deng; Mary Dooley; Emma T Geduldig; Robert M Greenberg; Mustafa M Husain; Styliani Kaliora; Rebecca G Knapp; Vassilios Latoussakis; Lauren S Liebman; William V McCall; Martina Mueller; Georgios Petrides; Joan Prudic; Peter B Rosenquist; Matthew V Rudorfer; Shirlene Sampson; Abeba A Teklehaimanot; Kristen G Tobias; Richard D Weiner; Robert C Young; Charles H Kellner
Journal:  Am J Geriatr Psychiatry       Date:  2019-10-12       Impact factor: 4.105

Review 3.  The Use of ECT in the Elderly-Looking Beyond Depression.

Authors:  Anthony N Chatham; Hadia Shafi; Adriana P Hermida
Journal:  Curr Psychiatry Rep       Date:  2022-07-13       Impact factor: 8.081

4.  The effects of anesthetic change on electrographic seizure duration during electroconvulsive therapy.

Authors:  James Luccarelli; Thomas H McCoy; Ryan J Horvath; Stephen J Seiner; Michael E Henry
Journal:  Brain Stimul       Date:  2021-07-20       Impact factor: 8.955

5.  Dexmedetomidine vs Propofol as an Adjunct to Ketamine for Electroconvulsive Therapy Anaesthesia.

Authors:  Tuğçe Yeter; Aybike Onur Gönen; Ercan Türeci
Journal:  Turk J Anaesthesiol Reanim       Date:  2022-04

6.  Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis.

Authors:  Taisuke Yatomi; Takahito Uchida; Akihiro Takamiya; Masataka Wada; Shun Kudo; Kazuki Nakajima; Hana Nishida; Bun Yamagata; Masaru Mimura; Jinichi Hirano
Journal:  Front Hum Neurosci       Date:  2022-07-08       Impact factor: 3.473

7.  Can Propofol Lead to an Increase in Seizure Threshold Over the Course of Electroconvulsive Therapy?

Authors:  Hande Gurbuz Aytuluk; Tahsin Simsek; Mehmet Yilmaz; Ayse Zeynep Turan; Kemal Tolga Saracoglu
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

8.  Uninterrupted Anesthesia Support and Technique Adaptations for Patients Presenting for Electroconvulsive Therapy During the COVID-19 Era.

Authors:  Venkatesan Thiruvenkatarajan; Ashok Dharmalingam; Allysan Armstrong-Brown; Alan Weiss; Susan Waite; Roelof Van Wijk
Journal:  J ECT       Date:  2020-09       Impact factor: 3.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.